Magenta Therapeutics Inc
F:3MT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nongshim Co Ltd
KRX:004370
|
KR |
|
LK Technology Holdings Ltd
HKEX:558
|
HK |
|
K
|
KSL Holdings Bhd
KLSE:KSL
|
MY |
Magenta Therapeutics Inc
Total Current Assets
Magenta Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magenta Therapeutics Inc
F:3MT
|
Total Current Assets
$115.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Magenta Therapeutics Inc
Glance View
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. The company is headquartered in Cambridge, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The firm's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. The company is developing product candidates to be used individually or, in some cases, in combination with each other.
